PDCD1 and hepatocellular carcinoma: A multicenter retrospective study demonstrated that FOLFOX-based HAIC in conjunction with TKI and PD-1 inhibitors therapy for HCC markedly enhanced patients’ survival prognosis in comparison to TKI in conjunction with PD-1 inhibitors therapy (35).